Share Name Share Symbol Market Type Share ISIN Share Description
Shield Therapeutics Plc LSE:STX London Ordinary Share GB00BYV81293 ORD 1.5P
  Price Change % Change Share Price Shares Traded Last Trade
  +4.00p +3.69% 112.50p 133,406 14:20:01
Bid Price Offer Price High Price Low Price Open Price
111.00p 114.00p 114.00p 108.50p 108.50p
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 11.88 -5.15 -2.00 131.7

Shield Therapeutics (STX) Latest News

More Shield Therapeutics News
Shield Therapeutics Takeover Rumours

Shield Therapeutics (STX) Share Charts

1 Year Shield Therapeutics Chart

1 Year Shield Therapeutics Chart

1 Month Shield Therapeutics Chart

1 Month Shield Therapeutics Chart

Intraday Shield Therapeutics Chart

Intraday Shield Therapeutics Chart

Shield Therapeutics (STX) Discussions and Chat

Shield Therapeutics Forums and Chat

Date Time Title Posts
24/5/201921:14Shield Therapeutics 615
23/4/201915:49Seagate Technology2,661

Add a New Thread

Shield Therapeutics (STX) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2019-05-24 15:29:04113.529,97411,322.48O
2019-05-24 15:15:58114.0012,00013,680.00O
2019-05-24 15:15:06112.748,8009,921.12O
2019-05-24 15:03:03112.741,7681,993.24O
2019-05-24 15:01:59111.785,0005,589.00O
View all Shield Therapeutics trades in real-time

Shield Therapeutics (STX) Top Chat Posts

Shield Therapeutics Daily Update: Shield Therapeutics Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker STX. The last closing price for Shield Therapeutics was 108.50p.
Shield Therapeutics Plc has a 4 week average price of 87p and a 12 week average price of 53.75p.
The 1 year high share price is 118.50p while the 1 year low share price is currently 26p.
There are currently 117,088,657 shares in issue and the average daily traded volume is 385,718 shares. The market capitalisation of Shield Therapeutics Plc is £131,724,739.13.
montyhedge: I'm 90% confident of approval its not a life threatening drug has I understand, so FDA giving it the nod seems nailed on to me, for the benefit its gives patients. I see the share price doubling coming months after 27th if given the ok, as deals get signed. Lets hopefully enjoy the ride.
stoneme: Yes. These gradual rises are better and leads to more sustainable : resilience in higher share price . .
sharestobuy: Are both still positive. Im guessing if it falls through,the share price will tank. Has anyone been to any investor events or AGMs to talk with the management of STX? Any positive signs, are they confident on approval?
nobbygnome: There is no doubt MMs can go short but in a situation like this it would appear to be suicidal. However it has been described to me that one MM will do all the stocks A-D and so on through the alphabet. So they have no real clue about the stocks they are dealing in and so just hope that the normal MM tricks to get sales will work. In this case I hope it doesn’t and I strongly suspect there will be a long slow climb in the share price ahead of the July decision!
timbo003: Other potential risks were also discussed at the meeting last night One obvious risk is the possibility of FDA finding problems with the Feraccru NDA. We were reassured that (according to the analysts) the current share price is already justified by the EU approval and marketing agreement with Norgine and given that Feraccru already has approval in Europe, it is unlikely that FDA will reject the application. Furthermore, the application was made before the completion of the head to head study, so Shield now have further data on an additional study which could be used to address any questions or to augment the SPC One other potential "risk" discussed was the possibility that oral iron supplements could in certain circumstances adversely affect the gut microbiome and the possibility that Feraccru could potentiate the problem (see link) This is something which has been considered and there has been a program of work conducted to show that this is a not an issue, this will publish in abstract form at the BSG annual meeting to be held in Glasgow in June
cf456: Liberum Capital upping its target price for the shares today. A significant uplift as well. From 80p to 116p. Target now more than 2x the current share price. --- "Liberum Capital today reaffirms its buy investment rating on Shield Therapeutics Plc (LON:STX) and raised its price target to 116p (from 80p)." hTTps://
cf456: All the 7s there TurboCharge. Quite a few others picking up on the story and buying in this morning too by the looks of it. The price shouldn't even be here. It dropped from 110p on study results which later turned out to be fine. But the market has been slow to pick up on the fact. Thus a great buying opportunity. Not only is there the potential re-rate back up to 110p, but there are other catalysts too and in particular the potential FDA approval in July worth an extra 85p on top of the share price according to Peel Hunt. And the company is fully cashed up until 2020. And of course the CEO is aligned with shareholders holding 8.7% of equity. That's nearly £5 million worth of his own money he has invested here. He will be particularly driven to get the share price moving northwards.
cf456: There's certainly blue sky on the chart to all the way to 110p. And the share price today should actually be above 110p since the reason for the original drop from 110p was completely invalidated in March 2018: --- 5 Feb 18: initial blended top-line data from Ferracru AEGIS-CKD study shows apparent failure to meet primary end-point 16 Mar 18: AEGIS-CKD detailed analysis shows study did in fact meet primary end-point 27 Mar 18: EU extends approved Ferracru indication to all adults with iron deficiency -- So in theory the share price should never have dropped in the first place since the AEGIS-CKD study results were positive all along. As per the most recent presentation: "Investment proposition – the recovery of the business from the consequences of the initial and ultimately incorrect AEGIS-CKD study results have not yet been reflected in the share price" hTTps:// - page 4
cf456: Sales momentum likely to accelerate with Norgine actively promoting Feraccru: "I have been encouraged by the sales performance of Feraccru® in the UK and Germany, where upward sales momentum has been maintained through the last twelve months despite the lack of active sales promotion since February 2018 and I believe that Norgine, with its much larger field-based sales team and readily available resources, is well placed to build on the positive momentum we saw in 2018 and drive the Feraccru business forwards in Europe." Increased interest in the shares in the weeks ahead in anticipation of a successful outcome in the US also likely. Peel Hunt reckon on an additional 85p on top of the share price for this. So that would mean the share price has the potential to triple from here on US success alone. This is bound to attract new investors.
cf456: Yes, definitely undervalued given the prospects. And obvious catalysts in the months ahead. Another positive is significant CEO skin in the game. His latest purchase was for £30k worth in Sep 2018. That took him to 10,163,496 shares. hTTps:// At the current 41p bid, that means he's got £4.1 million invested here. So he is very heavily incentivised indeed to drive the share price higher. Great to have management fortunes so closely aligned to those of shareholders.
Shield Therapeutics share price data is direct from the London Stock Exchange
Your Recent History
Shield The..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190525 07:32:01